The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...

Where early enthusiasm around IDMP programmes had waned in response to slow progress from EMA in Europe towards clarifying ...

Indian pharma notes revised Schedule M extension signals key step to avoid closure of units: Nandita Vijayasimha, Bengaluru Tuesday, January 7, 2025, 08:00 Hrs [IST] Indian pharma ...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today provided an update on recent business highlights and financial performance for 2024 and ...

Saman Gunatilake Emeritus Professor of Medicine and Neurologist University of Sri Jayewardenepura Key facts * Substandard and ...

The government has proposed extending the compliance deadline for revised Schedule M norms for pharmaceutical manufacturing.

Did you know that back in the 1980s and '90s, when South Korea was on the road toward becoming—but had yet to become—the ...

It specifies that by 2035, China expects to fully ensure the safety, efficacy and accessibility of drugs and medical devices, ...

Drugmakers in India may soon face stricter enforcement of quality standards. The revised Schedule M, which details ...

The expectations for the reduction of drug prices by stakeholders in the pharmaceutical sector have been dashed following the ...

500 crore (US$ 60.9 million) extends support required to existing pharma clusters and MSMEs across the country to improve their productivity, quality and sustainability ... Expansion in the Indian ...

Low-cost exposure to high-quality companies ... BlackRock’s commitment to building a first-class risk management system via its Aladdin analytics software. The software is also available ...